US Federal Circuit Breathes Life Into Viatris Symbicort Challenge
Company’s Stipulated Judgment Of Infringement Is Vacated And Remanded
Viatris may be able to move earlier than anticipated with its Breyna proposed generic version of Symbicort, after the US Court of Appeals for the Federal Circuit found that a lower court had misinterpreted claims of Symbicort patents for which Viatris has stipulated to infringement.
You may also be interested in...
Years after introducing the first US generic version of Advair, Viatris is leading the way on another respiratory launch with Breyna, the first US rival to Symbicort.
In the wake of a favorable US Court of Appeals for the Federal Circuit decision, Viatris has won FDA approval for the first generic Symbicort product. The ANDA sponsor’s management had recently declared itself “ready to launch if the opportunity presents itself in 2022.”
In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.